Sensitization of adenylate cyclase induced by a dopamine D2 receptor mutant: Inverse agonism by D2 receptor antagonists

被引:3
|
作者
Bullock, CM [1 ]
Li, C [1 ]
Li, M [1 ]
Bermak, JC [1 ]
Zhou, QY [1 ]
机构
[1] Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA
基金
美国国家卫生研究院;
关键词
adenylate cyclase; constitutively active receptors; dopamine D-2 receptor; G protein-coupled receptors; inverse agonism; sensitization;
D O I
10.1016/S0278-5846(01)00198-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
1. Mutations of residues in the third intracellular loops of several G-protein coupled receptors have been shown to confer constitutive activation. The authors investigated the effects of one such mutation in the dopamine D2 receptor. 2. Compared to the wild type D2, the mutant D2 receptor (D2T344K) showed a substantial increase in agonist affinity with affinity for antagonists unchanged. The increased agonist affinity was unaffected by pertussis toxin treatment, indicating it is an intrinsic property of the mutant receptor. The potency of dopamine for acute inhibition of forskolin-stimulated cAMP production in stably expressing Chinese Hamster Ovary (CHO) cells was higher for the mutant than the wild type receptor. 3. CHO cells stably expressing D2T344K displayed enhanced responses to forskolin-stimulated adenylate cyclase activity compared with cells stably expressing the wild type D2 receptor. The increased forskolin responsiveness of adenylate cyclase is similar to the sensitization previously observed with wild type D2 receptor after agonist treatment. Adenylate cyclase responsiveness of CHO cells stably expressing D2T344K receptor was not further increased by agonist treatment, 4. Sensitization was blocked by pertussis toxin and D2 receptor antagonists haloperidol, butaclamol, and clozapine, indicating inverse agonist activity of these compounds at D2T344K. Inverse agonist activity was further demonstrated by the finding that overnight treatment with these compounds drastically increased the density of the mutant receptor but had minimal effect on the density of the wild type receptor. 5. Taken together, these results suggest the authors have generated a constitutively active dopamine D2 receptor capable of sensitizing adenylate cyclase in the absence of agonist activation.
引用
收藏
页码:1387 / 1402
页数:16
相关论文
共 50 条
  • [21] Inverse agonist profiling of antipsychotics at the human D2 dopamine receptor
    Burstein, ES
    Ma, J
    Wong, S
    Weiner, DM
    Brann, MR
    [J]. SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 509 - 509
  • [22] Inverse agonism at D2 dopamine receptors - Relevance to antipsychotic action
    Strange, P
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S117 - S118
  • [23] The Universal 3D QSAR Model for Dopamine D2 Receptor Antagonists
    Zieba, Agata
    Zuk, Justyna
    Bartuzi, Damian
    Matosiuk, Dariusz
    Poso, Antti
    Kaczor, Agnieszka A.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (18)
  • [24] Bifeprunox:: Dopamine D2 receptor occupancy
    Devries, M
    Grahnen, A
    Bergström, M
    Långström, B
    Olsen, CK
    Brennum, LT
    Kreilgaard, M
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 243S - 244S
  • [25] ASPECTS OF THE STRUCTURE OF THE D2 DOPAMINE RECEPTOR
    STRANGE, PG
    [J]. TRENDS IN NEUROSCIENCES, 1990, 13 (09) : 373 - 378
  • [26] The regulation of D2 dopamine receptor expression
    R J Hitzemann
    [J]. Molecular Psychiatry, 1998, 3 : 198 - 203
  • [27] Targeting the dopamine D2 receptor in schizophrenia
    Seeman, Philip
    [J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2006, 10 (04) : 515 - 531
  • [28] PharmGKB summary: dopamine receptor D2
    Mi, Huaiyu
    Thomas, Paul D.
    Ring, Huijun Z.
    Jiang, Ruhong
    Sangkuhl, Katrin
    Klein, Teri E.
    Altman, Russ B.
    [J]. PHARMACOGENETICS AND GENOMICS, 2011, 21 (06): : 350 - 356
  • [29] REGULATORY MECHANISM OF D2 DOPAMINE RECEPTOR
    TANAKA, C
    FUJIWARA, H
    KUNO, T
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1984, 36 : P24 - P24
  • [30] The regulation of D2 dopamine receptor expression
    Hitzemann, RJ
    [J]. MOLECULAR PSYCHIATRY, 1998, 3 (03) : 198 - 203